Materias dentro de su búsqueda.
Materias dentro de su búsqueda.
-
2241por Hiroshima, Yuichi, Kondo, Masahide, Sawada, Takuya, Hoshi, Shu‐ling, Okubo, Reiko, Iizumi, Takashi, Numajiri, Haruko, Okumura, Toshiyuki, Sakurai, Hideyuki“…This study aimed to determine the cost‐effectiveness of PBT for unresectable, locally advanced pancreatic cancer (LAPC) as a replacement for conventional photon radiotherapy (RT). …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2242por Vietsch, Eveline E., Latifi, Diba, Verheij, Maaike, van der Oost, Elise W.A., de Wilde, Roeland F., Haen, Roel, van den Boom, Anne Loes, Koerkamp, Bas Groot, Doornebosch, Pascal G., van Verschuer, Victorien M.T., Ooms, Ariadne H.A.G., Mohammad, Farzana, Willemsen, Marcella, Aerts, Joachim G.J.V., Krog, Ricki T., de Miranda, Noel F.C.C., van den Bosch, Thierry P.P., Mueller, Yvonne M., Katsikis, Peter D., van Eijck, Casper H.J.Enlace del recurso
Publicado 2023
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2243por Huynh, Thi N. T., Hartel, Gunter, Janda, Monika, Wyld, David, Merrett, Neil, Gooden, Helen, Neale, Rachel E., Beesley, Vanessa L.“…Eighty-four pancreatic cancer patients and their carers were recruited. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2244por Tummala, Tej, Sevilla Uruchurtu, Ashley Sanchez, Cruz, Arielle De La, Huntington, Kelsey E., George, Andrew, Liguori, Nicholas R., Zhang, Leiqing, Zhou, Lanlan, Abbas, Abbas E., Azzoli, Christopher G., El-Deiry, Wafik S.“…Pancreatic cancer is a devastating disease with a poor prognosis. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2245por Das, Rishi, Abbott, Madeline R., Hadley, Scott W., Sahai, Vaibhav, Bednar, Filip, Evans, Joseph R., Schipper, Matthew J., Lawrence, Theodore S., Cuneo, Kyle C.“…PURPOSE: Patients with pancreatic cancer undergoing chemoradiation therapy may experience acute and chronic side effects. …”
Publicado 2023
Enlace del recurso
Enlace del recurso
Enlace del recurso
Online Artículo Texto -
2246por Haglund, C., Roberts, P. J., Kuusela, P., Scheinin, T. M., Mäkelä, O., Jalanko, H.“…Serum concentrations of the CA 19-9 antigen were determined in 91 patients with pancreatic cancer and in 111 patients with benign pancreatic, biliary and hepatocellular diseases. …”
Publicado 1986
Enlace del recurso
Enlace del recurso
Texto -
2247por Kawa, S., Tokoo, M., Hasebe, O., Hayashi, K., Imai, H., Oguchi, H., Kiyosawa, K., Furuta, S., Homma, T.“…A comparative study of a new tumour marker, CA242, and CA19-9 was conducted with special reference to their diagnostic usefulness in pancreatic cancer. CA242 showed sensitivity similar to that of CA19-9 for overall cases and early cases (stage I tumour) of pancreatic cancer. …”
Publicado 1994
Enlace del recurso
Enlace del recurso
Texto -
2248por Kayed, H, Jiang, X, Keleg, S, Jesnowski, R, Giese, T, Berger, M R, Esposito, I, Löhr, M, Friess, H, Kleeff, J“…Runt-related transcription factor-2 expression was silenced using specific siRNA oligonucleotides in pancreatic cancer cells (Panc-1) and immortalised pancreatic stellate cells (IPSCs). …”
Publicado 2007
Enlace del recurso
Enlace del recurso
Enlace del recurso
Texto -
2249“…We conducted a phase II trial of gemcitabine with S-1, oral fluorouracil (5-FU) prodrug tegafur combined with two modulators, 5-chloro-2, 4-dihydroxypyridine and potassium oxonate, to evaluate the activity and toxicity of such a combination in metastatic pancreatic cancer (MPC) patients. Patients who had pathologically proven pancreatic cancer with metastatic lesions were eligible candidates for entry into the study. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Texto -
2250por Tonini, G, Vincenzi, B, Santini, D, Scarpa, S, Vasaturo, T, Malacrino, C, Coppola, R, Magistrelli, P, Borzomati, D, Baldi, A, Antinori, A, Caricato, M, Nuzzo, G, Picciocchi, AEnlace del recurso
Publicado 2005
Enlace del recurso
Texto -
2251“…Pancreatic cancer is the eighth major form of cancer-related death worldwide, causing 227 000 deaths annually. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Texto -
2252por Tonini, G, Vincenzi, B, Santini, D, Scarpa, S, Vasaturo, T, Malacrino, C, Coppola, R, Magistrelli, P, Borzomati, D, Baldi, A, Antinori, A, Caricato, M, Nuzzo, G, Picciocchi, A“…Pancreatic cancer is one of the most aggressive gastrointestinal cancer with less than 10% long-term survivors. …”
Publicado 2005
Enlace del recurso
Enlace del recurso
Enlace del recurso
Texto -
2253por Nakamura, K, Yamaguchi, T, Ishihara, T, Kobayashi, A, Tadenuma, H, Sudo, K, Kato, H, Saisho, H“…The objective of this study was to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of S-1, an oral fluorouracil derivative, combined with gemcitabine, the current standard treatment for advanced pancreatic cancer (APC). The subjects were histopathologically proven APC patients with distant metastasis. …”
Publicado 2005
Enlace del recurso
Enlace del recurso
Enlace del recurso
Texto -
2254“…The present study examined the effect of a polymorphism of the interleukin (IL)-1b gene upon the inflammatory state and survival in pancreatic cancer. Genomic DNA was obtained from 64 patients with pancreatic cancer and 101 healthy controls. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Texto -
2255por Okusaka, T, Ito, Y, Ueno, H, Ikeda, M, Takezako, Y, Morizane, C, Kagami, Y, Ikeda, H“…This study was conducted to evaluate the efficacy and toxicity of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer. In all, 42 patients with pancreatic cancer that was unresectable but confined to the pancreatic region were treated with external-beam radiation (50.4 Gy in 28 fractions over 5.5 weeks) and weekly gemcitabine (250 mg m(−2), 30-min infusion). …”
Publicado 2004
Enlace del recurso
Enlace del recurso
Enlace del recurso
Texto -
2256Identification of a Specific Vimentin Isoform That Induces an Antibody Response in Pancreatic Cancerpor Hong, Su-Hyung, Misek, David E., Wang, Hong, Puravs, Eric, Hinderer, Robert, Giordano, Thomas J., Greenson, Joel K., Brenner, Dean E., Simeone, Diane M., Logsdon, Craig D., Hanash, Samir M.“…Pancreatic cancer has a poor prognosis, in part due to lack of early detection. …”
Publicado 2007
Enlace del recurso
Enlace del recurso
Texto -
2257por Chang, C. Y.“…However, physicians should be aware that in the presence of splenic vein thrombosis, this finding alone puts pancreatic cancer high on the differential diagnosis.…”
Publicado 1999
Enlace del recurso
Enlace del recurso
Texto -
2258“…BACKGROUND: This is the first investigation of its kind to explore the views of people affected by pancreatic cancer with regard to research priorities. Pancreatic cancer has an extremely poor outlook in terms of early diagnosis, effective treatment and survival. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso
Texto -
2259por Yamato, I, Sho, M, Nomi, T, Akahori, T, Shimada, K, Hotta, K, Kanehiro, H, Konishi, N, Yagita, H, Nakajima, Y“…METHODS: We investigated B7-H3 expression in 59 patients with pancreatic cancer by immunohistochemistry and real-time PCR. …”
Publicado 2009
Enlace del recurso
Enlace del recurso
Enlace del recurso
Texto -
2260por Takano, S, Sogawa, K, Yoshitomi, H, Shida, T, Mogushi, K, Kimura, F, Shimizu, H, Yoshidome, H, Ohtsuka, M, Kato, A, Ishihara, T, Tanaka, H, Yokosuka, O, Nomura, F, Miyazaki, M“…We investigated the serum phosphoprotein profile involved in pancreatic cancer (PaCa) by a novel approach that comprehensively measured serum phosphoproteins levels, and clinically applied this method to the detection of PaCa. …”
Publicado 2010
Enlace del recurso
Enlace del recurso
Enlace del recurso
Texto